BRPI0810882A2 - Derivados de ftalazinona e seu uso como medicamento para tratar câncer - Google Patents

Derivados de ftalazinona e seu uso como medicamento para tratar câncer

Info

Publication number
BRPI0810882A2
BRPI0810882A2 BRPI0810882-0A2A BRPI0810882A BRPI0810882A2 BR PI0810882 A2 BRPI0810882 A2 BR PI0810882A2 BR PI0810882 A BRPI0810882 A BR PI0810882A BR PI0810882 A2 BRPI0810882 A2 BR PI0810882A2
Authority
BR
Brazil
Prior art keywords
ftaazinone
cancer
drug
derivatives
ftaazinone derivatives
Prior art date
Application number
BRPI0810882-0A2A
Other languages
English (en)
Inventor
Keith Allan Menear
Marc Geoffrey Hummersone
Sylvie Gomez
Muhammad Hashim Javaid
Niall Morrison Barr Martin
Original Assignee
Kudos Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kudos Pharm Ltd filed Critical Kudos Pharm Ltd
Publication of BRPI0810882A2 publication Critical patent/BRPI0810882A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
BRPI0810882-0A2A 2007-04-10 2008-04-10 Derivados de ftalazinona e seu uso como medicamento para tratar câncer BRPI0810882A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91088707P 2007-04-10 2007-04-10
PCT/GB2008/001259 WO2008122810A1 (en) 2007-04-10 2008-04-10 Phthalazinone derivatives and their use as medicament to treat cancer

Publications (1)

Publication Number Publication Date
BRPI0810882A2 true BRPI0810882A2 (pt) 2014-10-29

Family

ID=39563291

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0810882-0A2A BRPI0810882A2 (pt) 2007-04-10 2008-04-10 Derivados de ftalazinona e seu uso como medicamento para tratar câncer

Country Status (16)

Country Link
US (1) US20080255128A1 (pt)
EP (1) EP2155726A1 (pt)
JP (1) JP2010523633A (pt)
KR (1) KR20100016366A (pt)
CN (1) CN101687855A (pt)
AR (1) AR066020A1 (pt)
AU (1) AU2008235308A1 (pt)
BR (1) BRPI0810882A2 (pt)
CA (1) CA2683682A1 (pt)
CL (1) CL2008001024A1 (pt)
IL (1) IL201460A0 (pt)
MX (1) MX2009010909A (pt)
TW (1) TW200900396A (pt)
UY (1) UY31014A1 (pt)
WO (1) WO2008122810A1 (pt)
ZA (1) ZA200907245B (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7151102B2 (en) * 2000-10-30 2006-12-19 Kudos Pharmaceuticals Limited Phthalazinone derivatives
GB0419072D0 (en) * 2004-08-26 2004-09-29 Kudos Pharm Ltd Phthalazinone derivatives
GB0428111D0 (en) * 2004-12-22 2005-01-26 Kudos Pharm Ltd Pthalazinone derivatives
GB0521373D0 (en) * 2005-10-20 2005-11-30 Kudos Pharm Ltd Pthalazinone derivatives
GB0610680D0 (en) 2006-05-31 2006-07-12 Istituto Di Ricerche D Biolog Therapeutic compounds
CN101484421A (zh) * 2006-06-15 2009-07-15 库多斯药物有限公司 作为parp抑制剂的2-氧基苯甲酰胺衍生物
WO2007144652A2 (en) * 2006-06-15 2007-12-21 Kudos Pharmaceuticals Limited Parp inhibitors
EP2041110A1 (en) * 2006-06-15 2009-04-01 Kudos Pharmaceuticals Limited 2 -oxyheteroarylamide derivatives as parp inhibitors
UY30639A1 (es) * 2006-10-17 2008-05-31 Kudos Pharm Ltd Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones
US20080280910A1 (en) * 2007-03-22 2008-11-13 Keith Allan Menear Phthalazinone derivatives
AU2008299721A1 (en) * 2007-09-14 2009-03-19 Astrazeneca Ab Phthalazinone derivatives
KR101598231B1 (ko) * 2007-10-17 2016-02-26 쿠도스 파마슈티칼스 리미티드 4-[3-(4-시클로프로판카르보닐-피페라진-1-카르보닐)-4-플루오로-벤질]-2ｈ-프탈라진-1-온
MX2010005070A (es) 2007-11-15 2010-05-24 Angeletti P Ist Richerche Bio Derivados de piridazinona como inhibidores de parp.
HUE030800T2 (en) * 2008-10-07 2017-05-29 Astrazeneca Uk Ltd Pharmaceutical Form No. 514
UY32790A (es) * 2009-07-15 2011-02-28 Astrazeneca Ab Compuesto de ftalazinona
WO2011058367A2 (en) 2009-11-13 2011-05-19 Astrazeneca Ab Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor
CN102372698A (zh) * 2010-08-10 2012-03-14 江苏恒瑞医药股份有限公司 酞嗪酮类衍生物、其制备方法及其在医药上的应用
EP3925962A1 (en) 2011-05-31 2021-12-22 Rakovina Therapeutics Inc. Tricyclic inhibitors of poly(adp-ribose) polymerase
KR101422725B1 (ko) * 2011-10-19 2014-07-25 한국화학연구원 신규한 프탈라지논 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 포함하는 ｍｃｈ 수용체-1 관련 질환의 예방 또는 치료용 약학적 조성물

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3813384A (en) * 1972-01-17 1974-05-28 Asta Werke Ag Chem Fab Basically substituted benzyl phthalazone derivatives,acid salts thereof and process for the production thereof
US4665181A (en) * 1984-05-17 1987-05-12 Pennwalt Corporation Anti-inflammatory phthalazinones
US5215738A (en) * 1985-05-03 1993-06-01 Sri International Benzamide and nicotinamide radiosensitizers
US5041653A (en) * 1985-05-03 1991-08-20 Sri International Substituted benzamide radiosensitizers
US5032617A (en) * 1985-05-03 1991-07-16 Sri International Substituted benzamide radiosensitizers
EP0222191B1 (de) * 1985-11-11 1991-01-30 ASTA Pharma AG 4-Benzyl-1-(2H)-phthalazinon-Derivate
CZ199593A3 (en) * 1992-10-02 1994-04-13 Asta Medica Ag Phthalazinone derivatives exhibiting anti-arrhythmic and analgesic activity and eliminating resistance to a plurality of medicaments (mdr)
US5587384A (en) * 1994-02-04 1996-12-24 The Johns Hopkins University Inhibitors of poly(ADP-ribose) synthetase and use thereof to treat NMDA neurotoxicity
US5648355A (en) * 1994-02-09 1997-07-15 Kos Pharmaceutical, Inc. Method of treatment of endogenous, painful gastrointestinal conditions of non-inflammatory, non-ulcerative origin
US5589483A (en) * 1994-12-21 1996-12-31 Geron Corporation Isoquinoline poly (ADP-ribose) polymerase inhibitors to treat skin diseases associated with cellular senescence
CA2205757C (en) * 1996-05-30 2006-01-24 F. Hoffmann-La Roche Ag Pyridazinone derivatives and their use as inhibitors of prostaglandin g/h synthase i and ii(cox i and ii)
US6197785B1 (en) * 1997-09-03 2001-03-06 Guilford Pharmaceuticals Inc. Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity
US6426415B1 (en) * 1997-09-03 2002-07-30 Guilford Pharmaceuticals Inc. Alkoxy-substituted compounds, methods and compositions for inhibiting parp activity
US6514983B1 (en) * 1997-09-03 2003-02-04 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage
US6635642B1 (en) * 1997-09-03 2003-10-21 Guilford Pharmaceuticals Inc. PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same
WO1999025340A1 (en) * 1997-11-14 1999-05-27 Eli Lilly And Company Treatment for alzheimer's disease
ITMI981671A1 (it) * 1998-07-21 2000-01-21 Zambon Spa Derivati ftalazinici inibitori della fosfodisterasi 4
AU3076700A (en) * 1999-01-26 2000-08-18 Ono Pharmaceutical Co. Ltd. 2h-phthalazin-1-one derivatives and drugs comprising these derivatives as the active ingredient
US6476048B1 (en) * 1999-12-07 2002-11-05 Inotek Pharamaceuticals Corporation Substituted phenanthridinones and methods of use thereof
US7151102B2 (en) * 2000-10-30 2006-12-19 Kudos Pharmaceuticals Limited Phthalazinone derivatives
US20030073692A1 (en) * 2001-08-07 2003-04-17 Pharmacia & Upjohn S.P.A. Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them
AUPS019702A0 (en) * 2002-01-29 2002-02-21 Fujisawa Pharmaceutical Co., Ltd. Condensed heterocyclic compounds
US7196085B2 (en) * 2002-04-30 2007-03-27 Kudos Pharmaceuticals Limited Phthalazinone derivatives
US7449464B2 (en) * 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
CN102107008B (zh) * 2003-12-01 2013-04-03 库多斯药物有限公司 用于治疗癌症的dna损伤修复抑制剂
GB0419072D0 (en) * 2004-08-26 2004-09-29 Kudos Pharm Ltd Phthalazinone derivatives
GB0521373D0 (en) * 2005-10-20 2005-11-30 Kudos Pharm Ltd Pthalazinone derivatives
UY30639A1 (es) * 2006-10-17 2008-05-31 Kudos Pharm Ltd Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones
AU2008299721A1 (en) * 2007-09-14 2009-03-19 Astrazeneca Ab Phthalazinone derivatives
UY31603A1 (es) * 2008-01-23 2009-08-31 Derivados de ftalazinona
EP2297142B1 (en) * 2008-06-24 2015-10-14 F. Hoffmann-La Roche AG Novel substituted pyridin-2-ones and pyridazin-3-ones

Also Published As

Publication number Publication date
CL2008001024A1 (es) 2009-01-02
TW200900396A (en) 2009-01-01
JP2010523633A (ja) 2010-07-15
ZA200907245B (en) 2010-07-28
CA2683682A1 (en) 2008-10-16
UY31014A1 (es) 2008-11-28
IL201460A0 (en) 2010-05-31
EP2155726A1 (en) 2010-02-24
US20080255128A1 (en) 2008-10-16
WO2008122810A1 (en) 2008-10-16
AR066020A1 (es) 2009-07-15
AU2008235308A1 (en) 2008-10-16
CN101687855A (zh) 2010-03-31
MX2009010909A (es) 2009-11-02
KR20100016366A (ko) 2010-02-12

Similar Documents

Publication Publication Date Title
BRPI0810882A2 (pt) Derivados de ftalazinona e seu uso como medicamento para tratar câncer
BRPI0906444A2 (pt) Compostos de 4-piridinona e seu uso para câncer
BRPI1013432A2 (pt) derivado de indolizina e uso do mesmo para propósitos médicos
BRPI0814231A2 (pt) Derivados de pleuromutilina e seu uso como antimicrobianos
BRPI0814267A2 (pt) Agentes citotóxicos compreendendo novos derivados de tomaicmicina e o seu uso terapêutico.
BRPI0920448A2 (pt) compostos spiro-oxindol e seu uso como agentes terapêuticos
BRPI1010621A2 (pt) derivado de imidazoquinolinonas, sua composição farmacêutica e seu uso
BRPI0810679A2 (pt) Derivados de 4-aza indol e seu uso como fungicidas
BRPI1008045A2 (pt) derivados de aminotetralina, composições farmacêuticas contendo-os, e seu uso em terapia
BR112013016772A2 (pt) composto, uso do composto, composição farmacêutica, oligonucleotídeo e conjugado
BRPI0817681A2 (pt) Compostos de tienopirimidina e pirazolopirimidina e seu uso como inibidores de mtor quinase e pi3 quinase
BRPI1010533A2 (pt) tetrahidroazolopirazinas sulfoniladas e seu uso como medicamentos
BRPI0914536A2 (pt) tiadiazoliloxifenilamidinas e o uso destas como fungicidas
BRPI0908225A2 (pt) derivados de piridazina e seu uso como agentes terapêuticos
BRPI0913885A8 (pt) tiadiazoliloxifenilamidinas e seu uso como fungicidas
BRPI0821248A2 (pt) Inibidores de cinesina como fármacos terapêuticos para câncer
AR066564A1 (es) Una combinacion farmaceutica sinergica para el tratamiento de cancer
BRPI0813600A2 (pt) formatação de pulso para egprs-2
BRPI1010024A2 (pt) derivados de aminopirrolidinona e uso dos mesmos
BRPI0819258A2 (pt) alguns derivados de 2-pirazinona e seu uso como inibidores da elastase neutrófila
BRPI0907931A2 (pt) Derivado de pirrolopirimidina como inibidor de pi3k e uso do mesmo
BRPI0810654A2 (pt) Tiadiazoliloxifenilamidinas e o seu uso como fungicidas.
BRPI0808846A2 (pt) fenoxifenilamidinas 3-substituídas e seu uso como fungicidas
BR112012001797A2 (pt) composto bicíclico e uso do mesmo para propósitos médicos
BRPI0810035A2 (pt) ligantes de receptor de vaniloide e seu uso para produção de medicamento

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2344 DE 08-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]